Gabather Investor Relations Material
Latest events
Investor Update
Gabather
Q2 2025
28 Aug, 2025
Q1 2025
28 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Gabather
Access all reports
Gabather AB is a pharmaceutical company dedicated to developing therapeutics for central nervous system diseases. The company focuses on creating novel drug candidates primarily for the treatment of neuropsychiatric disorders, including anti-psychotics, anti-depressants, anxiolytics, analgesics, and cognition-enhancing treatments. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
GABA
Country
🇸🇪 Sweden